Literature DB >> 31104566

Comparison Between Home and Ambulatory Morning Blood Pressure and Morning Hypertension in Their Reproducibility and Associations With Vascular Injury.

Qian-Hui Guo1, Yi-Bang Cheng1, Dong-Yan Zhang1, Ying Wang1, Qi-Fang Huang1, Chang-Sheng Sheng1, Ting-Yan Xu1, Yan Li1, Ji-Guang Wang1.   

Abstract

Morning blood pressure (BP) is recommended to be assessed by either 24-hour ambulatory or home BP monitoring. By which methods morning BP assessed is more reproducible and more closely associated with vascular injury remains unknown. We, therefore, addressed this issue in 1049 referred untreated outpatients (51.9% women; average age, 51 years) who had performed 24-hour ambulatory and 7-day home BP monitoring and vascular evaluations. Irrespective of the assessment methods, morning BPs were all significantly ( P≤0.027) associated with the arterial measures. The partial correlation coefficients of carotid-femoral pulse wave velocity and urinary albumin-to-creatinine ratio with home morning BPs were greater than those with the ambulatory morning pressures among the first 2 hours after awakening (0.21-0.37 versus 0.15-0.24; P<0.05). The associations with home morning systolic BP remained significant ( P≤0.002) after full adjustment for evening BP, whereas those with ambulatory morning BPs became nonsignificant after full adjustment for 24-hour BP except that of the carotid-femoral pulse wave velocity with ambulatory morning (6:00-10:00) systolic BP. Of the 135 subjects who had both home and repeated 24-hour ambulatory BP monitoring within 1 month, the coefficients of variation were ≈11% for ambulatory morning BPs and 5% for home self-measurements. In conclusion, morning BP, irrespective of the assessment methods and definitions, was generally reproducible and significantly associated with vascular indices. Nevertheless, home morning BP might be preferred than ambulatory measurements because of better reproducibility and stronger correlation with vascular indices.

Entities:  

Keywords:  blood pressure; blood pressure monitoring, ambulatory; hypertension

Mesh:

Year:  2019        PMID: 31104566     DOI: 10.1161/HYPERTENSIONAHA.119.12955

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

Review 1.  Current status of ambulatory blood pressure monitoring in Asian countries: A report from the HOPE Asia Network.

Authors:  Jinho Shin; Kazuomi Kario; Yook-Chin Chia; Yuda Turana; Chen-Huan Chen; Peera Buranakitjaroen; Romeo Divinagracia; Jennifer Nailes; Satoshi Hoshide; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Jam Chin Tay; Boon Wee Teo; Yu-Qing Zhang; Sungha Park; Huynh Van Minh; Tomoyuki Kabutoya; Narsingh Verma; Tzung-Dau Wang; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-11-07       Impact factor: 3.738

2.  The HOPE Asia network 2022 up-date consensus statement on morning hypertension management.

Authors:  Kazuomi Kario; Ji-Guang Wang; Yook-Chin Chia; Tzung-Dau Wang; Yan Li; Saulat Siddique; Jinho Shin; Yuda Turana; Peera Buranakitjaroen; Chen-Huan Chen; Hao-Min Cheng; Minh Van Huynh; Jennifer Nailes; Apichard Sukonthasarn; Yuqing Zhang; Jorge Sison; Arieska Ann Soenarta; Sungha Park; Guru Prasad Sogunuru; Jam Chin Tay; Boon Wee Teo; Kelvin Tsoi; Narsingh Verma; Satoshi Hoshide
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-09       Impact factor: 2.885

Review 3.  Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions.

Authors:  Ji-Guang Wang; Ma Lourdes Bunyi; Yook Chin Chia; Kazuomi Kario; Takayoshi Ohkubo; Sungha Park; Apichard Sukonthasarn; Jam Chin Tay; Yuda Turana; Narsingh Verma; Tzung-Dau Wang; Yutaka Imai
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-11       Impact factor: 3.738

Review 4.  The HOPE Asia Network activity for "zero" cardiovascular events in Asia: Overview 2020.

Authors:  Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-24       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.